Editorial of Special Issue "Surface-Functionalized Nanoparticles as Drug Carriers"
- PMID: 31861113
- PMCID: PMC6941103
- DOI: 10.3390/ijms20246352
Editorial of Special Issue "Surface-Functionalized Nanoparticles as Drug Carriers"
Abstract
Safe and effective delivery of therapeutics at the target site is the key to successful therapy. Nanocarriers can offer significant advantages over conventional dosage forms. Over the decades, nanoparticles have been extensively used to increase bioavailability, improve solubility and stability, reduce toxicities, and facilitate the controlled release of therapeutics. Further, nanoparticles have often been surface-functionalized with a variety of ligands to enhance circulation half-life and increase target-specificity. Although nanotechnology has shown significant therapeutic benefits for multiple biomedical applications, limited nanoparticle-based formulations have progressed to clinical trials, and only a few have reached the pharmaceutical market. This editorial is an introduction to the special issue entitled Surface-Functionalized Nanoparticles as Drug Carriers. We outline the scope of the special issue, summarize the results and conclusions of the nine articles published in this issue, and provide perspective on the application of surface-functionalized nanoparticles in the drug delivery field.
Keywords: bioavailability; controlled release; drug delivery; nanoparticles; surface-functionalized nanoparticles.
Conflict of interest statement
The authors declare no conflict of interest.
Similar articles
-
Relevance of Nanotechnology in Solving Oral Drug Delivery Challenges: A Perspective Review.Crit Rev Ther Drug Carrier Syst. 2020;37(5):407-434. doi: 10.1615/CritRevTherDrugCarrierSyst.2020032583. Crit Rev Ther Drug Carrier Syst. 2020. PMID: 33389846 Review.
-
Dosage form designs for the controlled drug release of solid dispersions.Int J Pharm. 2020 May 15;581:119274. doi: 10.1016/j.ijpharm.2020.119274. Epub 2020 Mar 29. Int J Pharm. 2020. PMID: 32234566 Review.
-
Comprehensive evaluation of chitosan nanoparticle based phage lysin delivery system; a novel approach to counter S. pneumoniae infections.Int J Pharm. 2020 Jan 5;573:118850. doi: 10.1016/j.ijpharm.2019.118850. Epub 2019 Nov 21. Int J Pharm. 2020. PMID: 31759993
-
The Brief Analysis of Peptide-combined Nanoparticle: Nanomedicine's Unique Value.Curr Protein Pept Sci. 2020;21(4):334-343. doi: 10.2174/1389203721666200210103841. Curr Protein Pept Sci. 2020. PMID: 32039679 Review.
-
Nanocarriers for oral drug delivery.J Drug Target. 2013 Jul;21(6):515-27. doi: 10.3109/1061186X.2013.789033. Epub 2013 Apr 26. J Drug Target. 2013. PMID: 23621127 Review.
Cited by
-
Biomimetic nanovaccines in cancer therapy: mechanisms, efficacy, and clinical translation.Mater Today Bio. 2025 Jul 18;34:102116. doi: 10.1016/j.mtbio.2025.102116. eCollection 2025 Oct. Mater Today Bio. 2025. PMID: 40791791 Free PMC article. Review.
References
-
- Teng C., Chai Z., Yuan Z., Ren L., Lin C., Yan Z., He W., Qin C., Yang L., Han X., et al. Desirable pegylation for improving tumor selectivity of hyaluronic acid-based nanoparticles via low hepatic captured, long circulation times and cd44 receptor-mediated tumor targeting. Nanomed. Nanotechnol. Biol. Med. 2020;24:102105. doi: 10.1016/j.nano.2019.102105. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources